Nachrichten zur Eli Lilly & Co. Aktie

ROUNDUP 2: Eli Lilly und Boehringer streichen Investitionen

(neu: Stellungnahmen von Schnieder, Ebling und Schweitzer) ALZEY/INGELHEIM (dpa-AFX) - Für den Wirtschaftsstandort…

ROUNDUP: Eli Lilly und Boehringer streichen Investitionen

ALZEY/INGELHEIM (dpa-AFX) - Deutliches Signal Richtung Berlin: Die Pharmakonzerne Eli Lilly und Boehringer Ingelheim streichen…

Eli Lilly halbiert Milliardeninvestition in Rheinland-Pfalz

ALZEY/INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly will wegen der Sparpläne der Bundesregierung im Gesundheitswesen…

Eli Lillys top dealmaker says dont be surprised to see more M&A that pushes Lilly into new areas

Eli Lillys new top dealmaker explains how the company changed its approach to M&A now that its the most valuable…

Eli Lilly Just Proved Gene Editing Could Be Pharmas Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Eli Lillys pipeline is an embarrassment of riches.…

Eli Lilly scores a first in major pharma milestone

Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly…

These 8 Words From Eli Lillys CEO Have Wall Street Turning Bullish

David Ricks was addressing the pharmaceutical titans latest hot product.…

Is Eli Lilly Starting an Nvidia-Style Run?

Lilly shares soared more than 18% in May.…

Eli Lilly sends strong message on vaccine strategy

Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain…

Lillys New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Heres What It Means for Investors

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.…

LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?

Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising…

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lillys valuation is a bit rich.…

CVS to restore coverage of Zepbound, add Eli Lillys obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lillys newly approved Foundayo pill on June 1.…

Eli Lilly stock gains after CVS adds Zepbound to drug list

Eli Lilly stock gains after CVS adds Zepbound to drug list…

Eli Lilly’s $4 Billion Vaccine Bet

In this week’s edition of InnovationRx, we look at the spreading Ebola epidemic, the Midas list health investors, Lilly’s trio…

Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion

Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one…

Lilly Goes on $20B Buying Spree as It Seeks Next Act

Bloombergs Michelle Davis joins Dani Burger on "Bloomberg Deals." Eli Lilly is on a record spending spree, announcing acquisitions worth…

Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to know

The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.…

Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts

LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.…

Is Eli Lilly Stock an Undervalued Stock to Buy?

Consumer demand for Eli Lillys weight-loss treatments continues to rise.…

Gewichtssenker-Hersteller Lilly übernimmt drei Impfstoffentwickler

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly steigt mit der Übernahme von gleich drei Unternehmen wieder…

Eli Lilly: Mit knapp 4 Mrd. USD werden drei strategische Übernahmen im Impfstoffsektor getätigt!

Strategische Neuausrichtung Eli Lilly (LLY) befindet sich aktuell in einer äußerst komfortablen finanziellen Lage und nutzt diese konsequent, um das…

Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms

Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company,…

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and Its All About Mounjaro

The efficacy of Eli Lillys new, still-in-development GLP-1 drug is gaining attention, but dont forget its older GLP-1 drugs just…

Eli Lilly weight loss drug data supports long-term obesity market position, says UBS

Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid…

Eli Lilly weight loss drug data supports long-term obesity market position, says UBS

Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid…

Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Want to hop off the AI trade? Goldman says buy these stocks that have nothing to do with it

Stocks such as Eli Lilly and Fortinet are less correlated to the artificial intelligence frenzy, according to Goldman Sachs.…

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Heres What You Need to Know.

The pharma giant is taking steps to expand its portfolio.…

Novo Nordisk faces new GLP-1 rival as Eli Lillys triple agonist sets weight-loss record

Citi said Eli Lilly and Cos (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1…

LLY Reports Third Phase III Win for Next-Generation Obesity Drug

Eli Lillys retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader…

Can Mounjaro, Zepbound & Foundayo Keep Fueling LLYs Growth Story?

Eli Lillys GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and…

Eli Lilly says next-generation weight loss drug clears crucial obesity trial

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing…

Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?

LLYs booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.…

Silver Economy Investing: Why the Healthcare Giants Are in Focus

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep…

Eli Lilly: Novo Nordisk Was Just A Warm-Up

…

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Pill Could Crash the Weight-Loss Party

This dark horse in the weight loss drug race is worth keeping on your watch list.…

GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.…

Eli Lilly Stock: Next Stop $2,000?

The company is riding an incredible tailwind.…

Eli Lilly loses Supreme Court appeal of $194 million fraud award

Eli Lilly loses Supreme Court appeal of $194 million fraud award…

US Supreme Court turns away Eli Lilly’s challenge to whistleblower law

US Supreme Court turns away Eli Lilly’s challenge to whistleblower law…

US Supreme Court turns away Eli Lillys challenge to whistleblower law

The U.S. Supreme Court declined on Monday to hear a challenge by drugmaker Eli Lilly to a Civil War-era whistleblower…

Novo Nordisks Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisks (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline...…

Novo Nordisks Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisks (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline...…

Hims And Hers Reshapes Growth With Branded GLP 1s And Eucalyptus Deal

Hims & Hers Health (NYSE:HIMS) is shifting its weight loss offering from compounded GLP-1 drugs to branded medications from partners…

Morgan Stanley flags vital Eli Lilly signal for 2026

Picture a drug so popular that, even in markets where a cheaper generic competitor had just launched, it still grew…

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lillys Growing Pressure?

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lillys expanding GLP-1 portfolio threatens its obesity market dominance.…

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.…

GLP-1 Wars: Winners & Losers

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1…

Should Hims & Hers Health’s AI and GLP-1 Push Require Action From Hims & Hers Health (HIMS) Investors?

In recent weeks, Hims & Hers Health launched its Labs AI agent to help users interpret biomarker lab results, expanded…